Dr. Vink began working with Athyrium in 2019 as a Senior Advisor. He is a seasoned senior executive working in the pharmaceutical industry for more than 30 years.
Dr. Vink serves as Chairman at Acacia Pharma Group Plc (EBR: ACPH) and Targovax ASA (TRVX-NO), both publicly listed biopharma companies based in the UK and Norway. Dr. Vink also serves as Chairman of VC-backed NMD Pharma, a neurology biopharma company in Denmark and is a board member at Santhera AG (SWX:SANN) and Spero Therapeutics (Nasdaq:SPRO). While serving at these companies, Dr. Vink has been involved in initial public listings, geographic expansions and achieving meaningful development and commercial milestones.
Previously, Dr. Vink served as Executive Vice-President and Chief Operating Officer at Cubist Inc., a leader in the anti-infective and acute care hospital market. He oversaw all worldwide commercial and technical operations as well as managing the company's P&L until the successful acquisition of Cubist by Merck. He joined Cubist in 2012 as Senior Vice President and Head of International Business Operations.
Prior to joining Cubist, he served as Senior Vice President, Global Head of Hospital Business and Biologics for Mylan Inc. In this role, he managed the global hospital business of the company. Earlier in his career he held several leadership positions across the industry, including Head of Global Biopharmaceuticals for the Sandoz division of Novartis, Vice President International Business for Biogen, and Head of Worldwide Marketing, Cardiovascular and Thrombosis at Sanofi-Synthelabo.
Dr. Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. He graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his MBA in 1992 at the University of Rochester.